TABLE 2.
COMPARISON OF ADVERSE EVENTS BETWEEN TRIALS OF MVA85A IN SUBJECTS WITH AND WITHOUT LATENT TUBERCULOUS INFECTION
| Latency Trial (n = 12) | Previous Trials of MVA85A* (n = 41) | |
|---|---|---|
| Local adverse events | ||
| Redness | 11 (92%) | 41 (100%) |
| Pruritus | 8 (67%) | 35 (85%) |
| Pain | 6 (50%) | 39 (95%) |
| Induration | 11 (92%) | 41 (100%) |
| Systemic adverse events | ||
| Fever | 0 (0%) | 5 (12%) |
| Flu-like | 4 (33%) | 17 (41%) |
| Arthralgia | 1 (8%) | 12 (29%) |
| Headache | 7 (58%) | 17 (41%) |
| Myalgia | 5 (42%) | 20 (49%) |
| Nausea | 0 (0%) | 6 (15%) |
| Tired | 7 (58%) | Not recorded |
| Vasovagal syncope | 0 (0%) | 1 (2%) |